FOXO1 and hepatocellular carcinoma: Inhibiting Treg cell differentiation with an anti-CD25 antibody or the Foxo1 inhibitor AS1842856 increased the therapeutic efficacy of Sora in HCC in vivo, representing a new strategy to increase the clinical efficacy of Sora and potentially other targeted therapies.